Le système thiorédoxine / thiorédoxine réductase dans la polyarthrite rhumatoïde (étude sur synoviocytes humains en culture)

Le rôle du système thiorédoxine/thiorédoxine réductase dans le maintien de l homéostasie redox cellulaire est étudié dans la polyarthrite rhumatoïde. Dans une première partie, la valeur de ces paramètres dans la circulation générale est établie en les reliant à l activité de la maladie évaluée par le DAS (disease activity score) et aux marqueurs classiques de l oxydation protéique. Puis, sur synoviocytes humains en culture, nous étudions l action des espèces radicalaires (anion superoxyde, peroxyde d hydrogène et peroxynitrite) et celle de cytokines pro-inflammatoires (tumor necrosis factor-a, interleukine-1b) en déterminant l activité de ce système et sa régulation. Enfin, nous mettons en évidence la génération d une forme tronquée de la thiorédoxine, nommée thiorédoxine80, molécule possédant des propriétés prolifératives. Au final, il apparaît que ce système joue un rôle important dans cette pathologie et puisse être au centre d une nouvelle approche thérapeutiqueThe role of the thioredoxin/thioredoxin reductase system implied in the homeostasis redox maintenance, is studied in rheumatoid arthritis disease. In a first part, we establish the value of these parameters in the general circulation by correlating them to the DAS (disease activity score), and to the protein oxidation markers. In a second part, on human synoviocytes in culture, we investigated the action of reactive species (e.g. superoxide anion, hydrogen peroxide, and peroxynitrite) and of pro-inflammatory cytokines (tumor necrosis factor-a, interleukine-1 b) by determining the activity of this system and its regulation. Lastly, we highlight the generation of a truncated form of the thioredoxin, named thioredoxin80 that exhibits proliferative properties. Thus, it appears that this system plays an important role in this disease, and can be a target in a therapeutic new approachPARIS-BIUP (751062107) / SudocSudocFranceF

Prognostic value of soluble urokinase plasminogen activator receptor in patients presenting to the emergency department with chest pain suggestive of acute coronary syndrome

International audienceINTRODUCTION: Soluble urokinase plasminogen activator receptor (suPAR) is a prognostic biomarker of cardiovascular disease. OBJECTIVES: We aimed to evaluate the early prognostic value of suPAR in patients presenting to the emergency department (ED) with chest pain suggestive of acute coronary syndrome (ACS). PATIENTS AND METHODS: In a post-hoc analysis from a multicenter study including patients with a chest pain < 6 h, suPAR concentrations at ED admission were studied according to the outcome at 30-days. RESULTS: 198 patients (median age 56 years) in whom 16% had an ACS, were included. Fifteen (7.3%) patients presented a 30-day event. At ED admission, median (IQR) suPAR concentrations were higher in patients with a 30-day event in comparison to patients without event (4.54 (3.09-8.61) vs. 2.72 (2.10-3.43) ng/mL, p < 0.001). The ROC curve AUC of suPAR for the prediction of a 30-days event was 0.775 [95%CI: 0.710-0.831]. The optimal threshold was 3.3 ng/mL, with a sensitivity of 73 [45-92] % and a specificity of 72 [65-79] %. The association of a suPAR < 3.3 ng/mL AND a NT-proBNP < 160 ng/L AND a HEART score < 4 had a negative predictive value of 99 [91-100] %. A suPAR value at admission above 3.3 ng/mL was independently and significantly associated with a 30-day event in chest pain emergency patients (OR 4.87 [1.35-17.51], p = 0.015). CONCLUSION: suPAR is a promising biomarker for early prediction of events in chest pain emergency patients

YAV++: a Software Platform for Medical Image Processing and Visualization

International audienceno abstrac

YAV++: a Software Platform for Medical Image Processing and Visualization

International audienceno abstrac